Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-17T05:17:21.911Z Has data issue: false hasContentIssue false
  • English
  • Français

Combined clozapine-lithium treatment for schizophrenia and schizoaffective disorder

Published online by Cambridge University Press:  16 April 2020

M Moldavsky ,
D Stein ,
R Benatov ,
P Sirota ,
A Elizur ,
Y Matzner  and
A Weizman
M Moldavsky
Affiliation:
Abarbanel Mental Health Center, 15 Keren Kayemet St, Bat-Yam, 59100, Israel affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
D Stein
Affiliation:
Abarbanel Mental Health Center, 15 Keren Kayemet St, Bat-Yam, 59100, Israel affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
R Benatov
Affiliation:
Abarbanel Mental Health Center, 15 Keren Kayemet St, Bat-Yam, 59100, Israel affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
P Sirota
Affiliation:
Abarbanel Mental Health Center, 15 Keren Kayemet St, Bat-Yam, 59100, Israel affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
A Elizur
Affiliation:
Abarbanel Mental Health Center, 15 Keren Kayemet St, Bat-Yam, 59100, Israel affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Y Matzner
Affiliation:
Hematology Unit, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel
A Weizman
Affiliation:
Geha Psychiatric Hosvital and Felsenstein Medical Research Center, Beilinson Medical Campus, Petah Tiqva, Israel affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv , Israel
Get access

Summary

Three adolescent and two adult patients suffering from chronic excited psychoses (either schizophrenia or schizoaffective disorder) resistant to traditional neuroleptics and clozapine were treated with combined clozapine-lithium. Improvement was assessed with the Positive and Negative Symptoms Scale, the Brief Psychiatric Rating Scale and the Clinical Global Impressions, administered before and during combined clozapine-lithium treatment. All patients demonstrated a significant improvement with this combination. There was no occurrence of agranulocytosis, neuroleptic malignant syndrome or other clinically significant adverse effects.

Keywords

clozapinelithiumschizophreniaschizoaffective disorder
Type
Short communication
Information
European Psychiatry , Volume 13 , Issue 2 , 1998 , pp. 104 - 106
Copyright
Copyright © Elsevier, Paris 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, FourthEdition. Washington, DC: American Psychiatric Association; 1994Google Scholar
Baldessarini, R, Frankenburg, F. Clozapine. A novel antipsychotic agent New Engl J Med 1991 ; 324(11) : 746-54Google ScholarPubMed
Boggs, DR, Joyce, RA. The hematopoietic effects of lithium Semin Hematol 1983; 20 : 129-38Google ScholarPubMed
Brotman, AW, Falk, WE, Gelenberg, AJ. Pharmacologic treatment of acute depressive subtypes In: Meltzer, HY ed. Psychopharmacology. The fhird genertrtion of progress. New York: Raven Press; 1987. p. 1038Google Scholar
Bryois, C, Ferrero, F. Clinical observation of 11 patients under clozapine-lithium association Eur Psychiatry 1993; 8 : 213-18CrossRefGoogle Scholar
Garcia, G, Crismon, ML, Dorson, PG. Seizures in two patients after the addition of lithium to a clozanine regimen J Clin Psychopharmacol 1994 ; 14(6) : 426-7Google ScholarPubMed
Gerson, SL. Clozapine - deciphering the risks N Engl J Med 1993 ; 329 : 204-5CrossRefGoogle ScholarPubMed
Guy, W. ECDEU Assessment Manual for Psychopharmacology Rockville: US Dept of Health and Human Services Publication (ADM); 1976. p 218-22Google Scholar
Hammond, WP, Dale, DC. Cyclic hematopoiesis: Effects of lithium on colony forming cells and colony stimulating activity in grey collie dogs Blood 1982 ; 59 : 179CrossRefGoogle ScholarPubMed
Hammond, WP, Rodger, ER, Dale, DC. Lithium augments GMCSA generation in canine cyclic hematopoiesis. Blood 1987 : 69: 117-23CrossRefGoogle ScholarPubMed
Kane, JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: An overview Br J Psychiatry 1992 ; 160 suppl 17 : 41-5CrossRefGoogle Scholar
Kane, JM, Honigfeld, G, Singer, J et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine Arch Gen Psychiatry 1988 ; 45 : 789-96CrossRefGoogle ScholarPubMed
Kay, SG, Opler, LA, Lindenmayer, JP. Reliability and validity of the Positive and Negative Symptoms Scale for schizophrenia. Psychiatry Res 1988; 23 : 99–110CrossRefGoogle Scholar
Kay, SR, Wolkenfeld, F, Murrill, LM. Profiles of aggression among psychiatric patients J Nerv Ment Dis 1988 ; 176 : 547-57CrossRefGoogle ScholarPubMed
McGrath, HE, Liang, CM, Alberico, TA, Quesenberry, PJ. The effect of lithium on growth Factor production in long-term bone marrow cultures Blood 1987; 70 : 1136-42CrossRefGoogle ScholarPubMed
Naber, D, Holzbach, R, Perro, C, Hippius, H. Clinical management of clozapine patients in relation to efficacy and sideeffects Br J Psychiatry 1992 ; 160 suppl 17 : 54-9CrossRefGoogle Scholar
Overall, JE and Gorham, DR. The Brief Psychiatric Rating Scale Psychol Rep 1962 ; 1O : 799–812CrossRefGoogle Scholar
Pope, HG Jr, Cole, JO, Choras, PT, Fulwiler, CF. Apparent neuroleptic malignant syndrome with clozapine and lithium J Nerv Ment Dis 1986 ; 174(8) : 493-5CrossRefGoogle ScholarPubMed
Sandoz Pharma Ltd. Clozaril, new drug application East Hanover: Sandoz Pharma Ltd; 1987Google Scholar
Valevski, A, Modai, I, Lahav, M, Weizman, A. Clozapine-lithium combined treatment and agranulocytosis Int Clin Pharmacol 1993 ; 8 : 63-5Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.